KRYS
Krystal Biotech, Inc.
NasdaqGS Healthcare United States
320,13 $US
-0.63% today
+29.65% YTD · +71.70% 1Y
25
Insider transactions
SEC Form 4 · AMF · BaFin — rolling 90 days
16
Hedge funds tracked
Latest available SEC 13F filings
71
/ 100
STRONG

Analysis Krystal Biotech, Inc. (KRYS) — Kairos Score 71/100

Composite score aggregating 8 smart money dimensions: insiders (SEC/AMF/BaFin), hedge funds, politicians & gurus, price momentum, valuation, analyst consensus, financial health, earnings momentum. The higher the score, the more favorable the institutional signals consensus.

💡 Detailed breakdown (the 8 sub-scores) available in the Premium dashboard.

About Krystal Biotech, Inc.

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Key info

👔
CEO
Mr. Krish S. Krishnan M.B.A., M.S.
📍
HQ
2100 Wharton Street, Suite 701, Pittsburgh, PA, 15203, United States
👥
Employees
295
💰
Market cap
9 475 475 456,00 $US
📊
P/E
40.4
💸
Dividend yield
0.00%

🕴️ Insider activity (90 days)

25 transactions — 0 buys and 25 sales reported by Krystal Biotech, Inc. executives.

KS
Krishnan Suma
President, R&D · 2026-09-04
Sell
KS
Krishnan Suma
President, R&D · 2026-09-04
Sell
KS
Krishnan Suma
President, R&D · 2026-09-04
Sell

🏦 Hedge Funds

16 institutional funds report a position on KRYS in their latest SEC quarterly filing.

FMR LLC
BlackRock, Inc.
Avoro Capital Advisors LLC
VANGUARD GROUP INC
VANGUARD PORTFOLIO MANAGEMENT LLC

📰 Recent news

15 recent articles on KRYS.

🧠 What makes Kairos Insider

Beyond raw data, we aggregate and score every smart money signal to give you a unique view.

🧠

Kairos Score 0-100

8-dimension composite score: insiders · hedge funds · politicians · momentum · valuation · health · analysts · earnings.

🎯

Insider Clusters

Detection of clustered purchases or sales by several executives in the same stock.

🏦

13F Hedge Funds

Berkshire, Pershing Square, Tiger Global, Bridgewater and other reporting funds.

📈

ETF Rotations

NANC & GOP (Pelosi & Republicans), GURU (top hedge funds), ARK (Cathie Wood). See who enters and exits each week.

🔥

Google Trends

Spot marked changes in search interest around the stocks being followed.

📧

Email alerts

Create your watchlist and receive a brief of events affecting your tickers.

Companies in the same sector as Krystal Biotech, Inc.

Official sources · Public data · SEC EDGAR — Form 4 & 13F · AMF — Executive filings · BaFin — Directors' Dealings · Yahoo Finance · Alpha Vantage

🔓 Unlock the full analysis

This public page only shows a preview. The full analysis of KRYS on the Kairos Insider dashboard includes:

✅ Full Kairos Score (8-axis radar + synthesis)
✅ History of all 25 insider transactions over 90 days
✅ All 16 detected institutional funds
✅ Thematic ETFs (ARK, BUZZ, NANC, GOP, JEPI…)
✅ Hot Stocks Google Trends
✅ Available history: AUM + rotations
✅ Fundamentals (P/E, PEG, EV/EBITDA, ROE…)
✅ Financial health (Altman Z, Piotroski F)
✅ Sector peers + recent earnings
See full analysis →
Analyze other tickers for free →

Free signup · Pro €19/month or €190/year